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Abstract
We introduce a novel per-gene measure of intra-gene DNA methylation variability (IGV)
based on the Illumina Infinium HumanMethylation450 platform, which is prognostic inde-
pendently of well-known predictors of clinical outcome. Using IGV, we derive a robust gene-
panel prognostic signature for ovarian cancer (OC, n = 221), which validates in two indepen-
dent data sets from Mayo Clinic (n = 198) and TCGA (n = 358), with significance of p =
0.004 in both sets. The OC prognostic signature gene-panel is comprised of four gene
groups, which represent distinct biological processes. We show the IGV measurements of
these gene groups are most likely a reflection of a mixture of intra-tumour heterogeneity and
transcription factor (TF) binding/activity. IGV can be used to predict clinical outcome in
patients individually, providing a surrogate read-out of hard-to-measure disease processes.
Introduction
Differences in DNA methylation (DNAm) levels are amongst the earliest changes in human
carcinogenesis [1] and are a hallmark of cancer [2], offering the potential for novel strategies to
predict cancer biology and outcome. The epigenetic differences which these changes give rise
to are more stable than differences in gene expression level. Gene expression levels, as mea-
sured by RNA, are subject to periodic and transient variability (such as diurnal variation and
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mRNA instability), which do not apply to DNAm. Identifying reliable indicators of differences
in DNAm patterns might provide a valuable lead for the development of DNA-based cancer
biomarkers in tissue and bodily fluids.
Ovarian cancer (OC) and endometrial cancer (EC) are the most common gynaecological
cancers [3]. Only one in three patients with advanced stage OC survive for five years after their
initial diagnosis [4]. Very little is known about OC biology and how to manipulate this disease
therapeutically. DNAm changes are important in cancer [5]; the epigenome is an interface
between the genome and the environment [6, 7], and hence DNAm changes can measure expo-
sure to environmental risk factors of cancer. DNAm biomarkers which represent a surrogate
for patterns of gene interaction have previously been associated with clinical outcome in a wide
variety of cancers [8], as well as specifically in women’s cancers [9].
Sample to sample variability of DNAm at specific genomic locations is known to be impor-
tant in the development of cancer [10, 11], and it has recently been shown that an increase in
intra-gene variability of DNAm (IGV), a measure of within-sample methylation variability
(Fig 1a), is highly associated with cancerous tissues in comparison to healthy [12]. Differential
methylation is the commonly-used method by which methylation levels are compared between
tissues, phenotypes and experimental conditions (equivalently to differential expression of
genes). Here, we develop a prognostic signature based on IGV which is independent of well-
known clinical prognostic features, and show that this IGV prognostic signature is likely a sur-
rogate readout reflecting a mixture of intra-tumour heterogeneity and transcription factor (TF)
binding/activity.
Results
Comparison of predictive robustness of per-gene methylation measures
in data
To assess the effectiveness and robustness of IGV compared to mean methylation levels, we
compared four per-gene methylation measures, based on mean methylation level and IGV (Fig
1). For each gene, we calculated mean methylation level and IGV, separately for the promoter
(TSS200) and gene body regions, by using the Illumina Infinium HumanMethylation450 plat-
form specifications of the CpGs in these regions for each gene. We considered different
Fig 1. Per-gene methylation measures. (a) The meanmethylation level over a specific genomic region is
calculated separately for the TSS200 (promoter) and gene body genomic regions. The blue curve indicates
the new position of the red curve after an additive global shift in methylation level, which might be due to
technological or other experimental factors, and the difference between the horizontal red and blue lines
(mean levels) illustrates the effect of this shift on the meanmethylation level. (b) The intra-gene methylation
variability (IGV) is calculated from the variation around the mean methylation level, i.e., from the dashed
vertical lines, and is similarly calculated separately for the TSS200 and gene body genomic regions. The
vertical green lines are changed very little compared to the vertical red lines, illustrating that such a global
additive shift in mean methylation level has much less effect on IGV, which is therefore referred to as a ‘self-
calibrating measure’.
doi:10.1371/journal.pone.0143178.g001
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genomic regions separately, because methylation patterns vary greatly from one genomic
region to another, and the effect of methylation level on gene regulation varies according to
genomic region. The four measures we compared, are as follows:
• TSS200 mean methylation
• TSS200 IGV
• Gene body mean methylation
• Gene body IGV
We obtained genome-wide DNAm profiles, via the Illumina Infinium HumanMethyla-
tion450 platform, from 218 primary OC samples. For each of the four measures described, we
used ‘Elastic Net’ [13, 14] to find a prognostic selection of genes. Elastic net has been found to
be an optimal linear modelling method to identify groups of genes which act together as part of
a common biological process [15]. It is a regression method which ‘chooses’ the set of genes
which model the data best, trying to include as few genes in the model as possible, whilst ensur-
ing that the model predicts the outcome of interest as accurately as possible. In doing so, it dis-
cards genes which do not provide useful information, or which provide repeated information.
As our aim is to find a minimal set of genes to use as a prognostic signature, it is important to
note that amongst these genes, there will be groups of genes for which their IGV contains
redundant or overlapping information, and there will be groups of genes for which IGV con-
tains complementary information for each gene. Hence we chose to use the Elastic Net tech-
nique to accurately discern such a non-redundant grouping of genes as a minimal predictive
set from very many possibilities, genome wide. We note that whilst this methodology may
seem complex in this context, simpler methodology would not be able to discern these parsi-
monious groupings of genes in which overlapping and redundant information is kept to a
minimum.
We assessed the effectiveness of the per-gene methylation measures as prognostic measures
by randomly dividing the data into two portions: a ‘training set’, and a ‘test set’. Elastic Net was
used to select genes and fit a model to the training set, and the ability of this gene selection and
model to blindly predict patient survival outcome (adjusted for clinical covariates) was assessed
using the test-set. This was repeated 2001 times, and significantly predictive selected groups of
genes were defined according to false discovery rate (FDR) adjusted [16] p-value (i.e., FDR
q-value)< 0.1 (Fig 2a). As shown in Fig 2b, only gene body IGV predicts well.
Derivation of an ovarian cancer prognostic signature, and IGV
prognostic score
We used IGV to derive an OC DNAm prognostic signature (Fig 2c), based on gene-body IGV
(from here on simply referred to as ‘IGV’). We did this by determining a consensus on a set of
genes predictive of survival, by following the same procedure of splitting data into test and
training sets, and then assessing the gene selection and fitted model for their ability to blindly
predict patient survival outcome (adjusted for clinical covariates) in the test set. In order to
ensure convergence to a stable result, we made 105 such partitions of the data, each resulting in
a predictive selection of genes. Of these, 8281 were found as significant (FDR q< 0.1), and sig-
nificance for each gene was then calculated based on the number of significant models in
which that gene appeared. 679 genes were selected like this for inclusion in the OC prognostic
signature at a significance level of FDR q< 0.05, with the least significant gene present in 1057
out of 8281 model fits. The top 100 most significant of these genes are shown in Supplementary
Tables (S1 File).
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Genes often act together as part of biological pathways, and processes. Hence, we can expect
that these 679 OC prognostic signature genes can be represented by a smaller number of
underlying biological processes, which are important to disease progression. Grouping genes
with similar experimental measurements by using clustering methodology is well established as
an effective approach for determining clinically relevant prognostic markers [17, 18]. Hence, to
uncover such groupings in the 679 genes of our OC prognostic signature, we carried out con-
sensus clustering [19], to identify groups of genes with similar patterns of IGV across patients.
Each cluster identified in this way reveals a different IGV trend, and therefore may correspond
to a different underlying biological process, which gives rise to the pattern of IGV observed in
that cluster. The clustering was carried out separately for genes which were individually associ-
ated with worse patient survival outcome for increased IGV (‘hyper’ genes) and for decreased
IGV (‘hypo’ genes). The result was four clusters: two from the hyper genes, called clusters
‘hyper 1’ and ‘hyper 2’, and two from the hypo genes, called clusters ‘hypo 1’ and ‘hypo 2’; they
are shown in Supplementary Tables (S1 File). The mean IGV of the genes of each of the four
clusters gives an IGV ‘cluster score’, for each cluster and for each patient, which are taken to be
representative of the different IGV trends, and corresponding underlying biological processes,
within the OC prognostic signature.
We then calculated an IGV prognostic score, by fitting a multivariate Cox proportional haz-
ards model (accounting also for clinical covariates) to the four IGV cluster scores. It was not
possible to fit such a model to the full set of 10014 genes, because there are many more
Fig 2. Overview of methods. (a) Methodology overview for comparison of the four per-gene methylation measures. (b) Results of this comparison. (c)
Methodology overview for calculation of ovarian cancer IGV prognostic score.
doi:10.1371/journal.pone.0143178.g002
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predictor variables (genes) than samples [20]. However, reducing the prognostic signature to 4
cluster scores, i.e., 4 predictors, allows the Cox proportional hazards model to be fitted. This
results in a model coefficient for each cluster score/predictor; these are used to calculate the
IGV prognostic score. The IGV prognostic score is a one-number prognostic indicator for a
single sample/patient, and we note that it must be calculated based on all four cluster scores, to
be significantly prognostic.
The median of this IGV prognostic score was used to divide the patients of the main OC
data set into better and worse prognostic groups, shown in Fig 3a and 3b. The IGV prognostic
score was validated in two independent sets of cancers derived from the Mullerian tract. A new
OC set from the Mayo Clinic (n = 198) confirmed the prognostic capacity of the IGV prognos-
tic score in both univariate (Fig 3c) and multivariate (Fig 3d) analyses. In order to test whether
the IGV prognostic score is only limited to OC, or whether it is also predictive in other cancers
which arise from the same embryological structure (i.e., the Mullerian duct), we applied our
prognostic score to a publically available uterine corpus endometrioid carcinoma (UCEC) set
from The Cancer Genome Atlas (TCGA) [21] (n = 358). Again, in both univariate (Fig 3e) and
multivariate (Fig 3f) analyses, we were able validate the IGV prognostic score.
We note that using the median prognostic score from the main OC data-set (the training
set) to dichotomise the patients of the Mayo OC and TCGA UCEC validation sets makes this a
true assessment of the prognostic ability of this methodology. This is because by this method,
the patients of the validation sets are classified one by one into a better or worse prognostic
group, in terms of their DNAmmeasurements only. This classification is done according to a
threshold or boundary dividing these prognostic groups (i.e., the median of the prognostic
score in the training data-set), and this threshold is set entirely independently of these valida-
tion data-sets.
IGV and intra-tumour heterogeneity
We suggest that the IGV cluster scores are each representative of different biological processes,
important for disease outcome. But what are these processes? To try to find some answers to
this question, we first hypothesised that intra-tumour heterogeneity might be a reflection of
IGV. The subject of intra-tumour heterogeneity is currently receiving a great deal of attention,
uncovering much spatial and temporal diversity in genomic processes within individual
tumours [22]. Ideally, the DNA methylome of individual cells from the same tumour sample
should be analysed to address this question. As an alternative approach, we use here cross-sam-
ple methylation variance (i.e., mean methylation variance of individual CpGs of a specific
gene-body region), as a measure of intra-tumour methylation heterogeneity, in order to assess
how this varies as a function of IGV (Fig 4a). Cross-sample methylation variability is also a
measure of how similar the methylation profiles are for the gene, across samples. If cross-sam-
ple methylation variability were a reflection of IGV, as IGV increases, we would expect to see a
consistently increasing cross-sample methylation variance (Fig 4b, expected proportional fit).
However, instead we see a pattern in which for low IGV, cross-sample methylation variance
increases, whereas for high IGV, cross-sample methylation variance decreases again and is very
low for the highest IGV values. In order to validate this further, we analysed two additional
data sets, for which several samples from different regions of the same cancer have been taken.
The first additional data-set is derived from endometrial cancers, where independent samples
have been taken from 2 or 3 primary cancer and metastatic sites, in each of 10 patients (Fig 4c,
one curve of best fit is shown per patient). The second is derived from prostate cancers, where
8 independent samples have been taken from the same tumour, from each of five cancer
patients [23] (Fig 4d, one curve per patient). The pattern of these curves is almost identical to
DNAMethylation Variability Is a Prognostic Marker
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Fig 3. IGV OC prognostic signature validation. (a), (c) and (e): Comparison of survival curves of groups defined by the IGV prognostic score, in: (a) the
main OC data set, (c) the Mayo Clinic OC validation set, (e) the uterine cancer TCGA validation set. The groups are divided by the median IGV prognostic
score derived in the main OC DNAm data-set. The hazard ratio (HR) is displayed with 95%C.I. in brackets, with corresponding p-value calculated by
univariate Cox regression. (d), (e) and (f): Multivariate Cox regression comparing the same groups defined by the IGV prognostic score.
doi:10.1371/journal.pone.0143178.g003
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the intra-tumour heterogeneity studies, in the main OC study which we used to identify the
OC prognostic signature (Fig 4b), and in basal samples from the TCGA breast-cancer invasive
carcinoma (BRCA) data-set (Fig 4e). The overlap of genes in all regions of these plots is also
highly significant across data sets (Fig 4f–4h).
The genes of cluster hyper 1 are somewhat over-represented in the left half of Fig 4b, where
IGV is lower, and cross-sample methylation heterogeneity is typically higher. This suggests
Fig 4. Comparison of IGV with Intra-Tumour Heterogeneity. (a) Cross-sample variability of methylation (Intra-tumour heterogeneity) and IGV are
calculated in different and complementary directions. The heatmap displays the methylation profile of a single gene (horizontal axis), across multiple samples
(vertical axis). (b)-(e) A characteristic pattern of high cross-sample variability (intra-tumour heterogeneity) when IGV is low, and vice-versa, is consistently
observed across different studies: (b) Main OC data-set, (c) Endometrial cancer intra-tumour heterogeneity data-set, (d) prostate cancer intra-tumour
heterogeneity data-set, (e) BRCA basal data-set. (f)-(h) The overlap of genes in each region of (b) with genes in equivalent regions of (c)-(e) is highly
significant. In (c) and (d), each line relates to samples from a single patient, and is a best fit curve equivalent to that shown in (b) and (e). In (b), odds-ratios
and p-values at the top of the plot show enrichment of the genes of each cluster, either side of the median IGV of the prognostic signature. Abbreviations: ITH
(intra-tumour heterogeneity), OC (ovarian carcinoma), BRCA (breast cancer invasive carcinoma).
doi:10.1371/journal.pone.0143178.g004
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that the increased IGV of these genes is associated with intra-tumour heterogeneity. However,
the genes of clusters hyper 2 and hypo 2 fall mostly in the region of high IGV and low cross-
sample methylation variability (towards the right of Fig 4b). This means that, for the genes of
these clusters, their methylation profiles tend to be similar in different samples from the same
tumour, or from different tumours. In the case of cluster hyper 2, this corresponds to high
methylation variability within a single gene in poor prognostic cases, and that this variability is
consistently similar throughout the tumour and between tumours. Hence, the genes of cluster
hyper 2 show high IGV in poor prognostic cases, yet appear to be independent of intra-tumour
heterogeneity. Therefore, we speculate that the increased IGV of these genes is a tumour-cell
inherent phenomenon, independent of intra-tumour heterogeneity. This means that the IGV
prognostic signature combines measures of intra-tumour heterogeneity, with those of indepen-
dent, tumour-cell inherent phenomena. We note that the terms ‘hyper’ and ‘hypo’, here relate
to change, rather than absolute level. For example, S1 Fig shows that cluster hypo 2 has the
highest IGV of any cluster; however, the IGV of this cluster is actually lower in poor compared
to good prognostic cases.
The genes defining cluster hypo 1 have the highest mean cross-sample methylation variabil-
ity (Fig 4), as well as the highest mean methylation level (S2 Fig), and the low IGV of the hypo
1 genes is associated with poor prognosis. At first, it seems difficult to explain that poor prog-
nostic cancers have lower IGV in the hypo1 genes, yet these hypo1 genes also represent high
sample-sample methylation heterogeneity. To explain this, we used a measure of CpG-CpG
methylation variability, which we call the mean derivative [12], which is calculated as the aver-
age absolute difference in methylation levels between adjacent CpGs of the gene-body of a
gene, in a single sample. The Illumina HumanMethylation 450K array measures the methyla-
tion levels of specific CpG loci, averaged across a mixed-up sample of many cells. Fig 5a and 5b
shows two examples of how high methylation variability at the single-cell level might manifest
in measurements acquired using this technology.
In the example of Fig 5a, we see that there is little cell-cell heterogeneity, although there is
much variability within a gene. Hence, this results in measurements of high IGV, and low
cross-sample methylation variability, as we see in cluster hyper 2. Then Fig 5b shows an exam-
ple in which there is much cell-cell variability, as well as much variability within a gene. The
result is that the cross-sample methylation variability of the array measurements is high, but
because the highly variable methylation profiles ‘average out’ across the mixed-up cells in the
sample, the net result is a measurement with low IGV. To examine whether this hypothesis is
plausible, we use the mean derivative measure of CpG-CpG methylation variability (Fig 5c). By
considering how heterogenous this CpG-CpG variability is across samples (Fig 5d), we are able
to confirm that in the genes of cluster hypo 1, the CpG-CpG methylation variability tends to be
more different across different cells than in any other cluster, as reflected by the high variance
of the mean-derivative measurements. We are also able to confirm from Fig 5d that in the
genes of cluster hyper 2, the CpG-CpG methylation variability tends to be less different across
different cells than in any other cluster, as indicated by the low variance of the mean derivative.
Hence, these data support the model shown in Fig 5a and 5b for genes in cluster hyper 2 and
hypo 1, respectively.
Functional role of transcription-factor activity in IGV
As the genes comprising cluster hyper 2 seem to show the same IGV in most cells of the
tumour, but the high IGV of the cluster hyper 2 genes is associated with poor prognosis, we
deem the cluster hyper 2 IGV to be a ‘consistent tumour-cell inherent phenomenon’, which is
likely to be regulated by differential binding of transcription factors (TF). Therefore, we
DNAMethylation Variability Is a Prognostic Marker
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examined TF binding to the gene body regions of the OC prognostic signature genes, and
tested the correlation of TF expression with the IGV of the genes they bind to (in a TCGA set
of basal breast cancers). We found that each prognostic signature cluster shows its own distinc-
tive pattern of TF binding (Fig 6a), which we can hypothesise is associated with the biological
processes responsible for the characteristic pattern of IGV observed in that cluster.
Fig 5. Heterogeneity and the effects of cell mixing on the 450K array. The 450K array provides methylation measurements from a mixed-up sample of
multiple cells. (a) An example of a methylation pattern which is highly variable, in a similar way across cells. This leads to low cross-sample heterogeneity,
and high IGV, as in cluster hyper 2. (b) An example of a methylation pattern which is highly variable, but in a heterogenous way across cells. This leads to
high cross-sample heterogeneity, however the net effect of averaging the methylation profiles across the mixed up sample of many cells gives a
measurement with low IGV, as in cluster hypo 1. (c) A measure of CpG-CpGmethylation variability, calculated as the mean derivative, or the mean absolute
difference in methylation level between adjacent CpGs. (d) The variability of the mean-derivative measure across samples quantifies the heterogeneity of the
CpG-CpGmethylation variability. Cluster hyper 2 is low according to (d), and hence corresponds to a pattern such as (a). Cluster hypo 1 is high according to
(d), and hence corresponds to a pattern such as (b).
doi:10.1371/journal.pone.0143178.g005
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Transcription factor binding site information, obtained from the ENCODE (Encyclopedia
of DNA Elements) project [24], was available for the gene body regions of all the genes repre-
sented on the Illumina HumanMethylation 450K array, for 55 transcription factors. We tested
each of these 55 TFs, for significantly increased or decreased binding to the genes of each prog-
nostic signature cluster. Cluster hypo 2 only consists of 19 genes, and hence we would not
expect to see many significant correlations, due to small sample size. But interestingly, for clus-
ter hyper 2 (comprised of genes whose methylation levels vary little across tumours but show
higher IGV), we see that 20% (11/55) of the TFs tested show significantly more binding to
these genes than expected, whereas 16% show significantly less binding than expected. For the
gene clusters for which DNAm varies across/within tumours and have generally low IGV (clus-
ters hyper 1 and hypo 1), not a single TF showed higher than expected binding, whereas 27%
and 38% of TFs show lower than expected binding to the genes comprising cluster hyper 1 and
hypo 1, respectively. This is consistent with the idea that TF binding is involved in distinct and
different processes associated with IGV and methylation heterogeneity within a sample.
We also wanted to test the actual correlation of expression of the TFs with IGV of the genes
they bind to, and genes they do not bind to, genome-wide. To do this, we used a TCGA set of
basal breast cancers, for which 450k methylation data as well as expression data exist. We have
already established a high degree of similarity in behaviour of our prognostic signature genes in
OC and these TCGA BRCA basal samples (Fig 4). Further, it has been comprehensively demon-
strated by the TCGA consortium that high-grade serous ovarian and uterine and BRCA basal
cancers are extremely molecularly similar [25]. Fig 6b and 6c show TFs with significantly more
positive, and more negative, correlation with IGV of the genes they bind to, compared to the
genes they do not. It is interesting that the two most highly ranked transcription factors accord-
ing to increased positive correlation of their expression with IGV in bound genes, Rad21 and
Brg1 (SMARCA4), are both parts of chromatin modifying complexes with relevance to stem cell
identity [26, 27]. In particular, Brg1 (SMARCA4) has been shown recently to have particular rel-
evance to small-cell ovarian cancer [28–30]. The overlap between the TFs which show signifi-
cantly different binding patterns in relation to the OC prognostic signature genes, and TFs
which display significantly altered correlation of their expression with IGV of genes they bind
to, is shown in Fig 6d. Much relevant detail has already been reported about most of these TFs
(references noted in the figure): either their binding is influenced by methylation (or vice-versa),
or they are involved with chromatin remodelling in stem cells. The TFs shown in Fig 6d are
important to the processes underlying disease progression, which are associated with our OC
prognostic signature (TFs with known relevance are indicated with a reference to the relevant
study [26, 31–40]). Therefore we hypothesise that IGV, in our OC prognostic signature gene
panel, represents a surrogate measure for their activity and role in disease transformation.
Association of prognostic signature CpGs with CpG islands and
enhancer regions
The location of CpGs relative to CpG islands (CGIs) is known to be an important determinant
of the functional role of these CpGs [41]. We tested for enrichment of probes annotated to the
CGI regions ‘island’, ‘shore’ and ‘shelf’ amongst all gene body annotated probes, as well as
probes annotated to gene bodies of the genes of our prognostic signature, and of the four clus-
ters. While we found that gene body probes were overall significantly depleted for probes in
these CGI regions, the opposite was true for gene bodies of our prognostic signature (see Sup-
plementary Tables in S1 File). This effect appears to be largely driven by the second cluster.
This indicates a prominent role for CpG islands in the relevant areas of the genes of our prog-
nostic signature.
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Fig 6. Transcription Factor Binding and Expression Correlation with IGV. (a) False discovery rate adjusted p-values and odds-ratios (OR) show
enrichment of binding of specific transcription factors (TFs), to the gene body regions of the genes of each cluster. TFs for which binding is significantly over
or under enriched (Fisher’s exact test, FDR q < 0.05) are coloured green and red, respectively. (b) TFs which show significantly more positive correlation with
IGV of the genes they bind to, compared to the genes they do not bind to. (c) TFs which show significantly more negative correlation with IGV of the genes
they bind to, compared to the genes they do not bind to. (d) TFs which are significant according to (a) and either (b) or (c); TFs with known relevance are
indicated with a reference to the relevant study. The lack of enrichment of TF binding to the genes of cluster hypo2, is a reflection of the small number (19) of
genes in this cluster.
doi:10.1371/journal.pone.0143178.g006
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Location of CpGs relative to enhancer regions is also known to be relevant to the functional
role of CpGs. We tested whether there was enrichment of methylation sites annotated to
enhancers in gene bodies in general, finding that there is, as would be expected. Then, we tested
enhancer enrichment similarly in the prognostic signature gene bodies, and the gene bodies of
the individual clusters. We found that there is an even greater enrichment in the prognostic sig-
nature gene bodies than in gene bodies in general, which is consistent with IGV being mediated
by transcription factor binding. This effect seems to be driven particularly by the ‘hypo’ clus-
ters, for which methylation variability decreases with worse prognosis. These results are shown
in Supplementary Tables (S1 File).
Discussion
We have found that IGV (a per-gene measure of intra-gene variability of DNAm) is a far more
robust prognostic marker tool than mean methylation levels: Fig 2b indicates that gene body
IGV has the potential to become an effective prognostic tool. While it is true that the Illumina
HumanMethylation 450K array provides more DNAmmeasurements for the gene-body than
for any other genomic region, and hence gene-body derived measures can potentially provide
more information than those derived from the promoter region when using this technology,
this is unlikely to be the whole explanation for its effectiveness in this study.
We note that it has previously been found that the most variably methylated CpGs occur
more frequently in gene bodies than in promoters [42]. However, while it is well established
that promoter methylation in CpG-dense regions is associated with gene repression [41], the
effects of gene-body methylation are less clear. Gene body methylation has recently been
shown to have a direct effect on gene expression level [43], however it may also be associated
with other influences on transcription and translation, such as prevalence of alternatively
spliced gene products [41]. Findings are also starting to emerge that gene-body methylation
may be an effective therapeutic target in cancer [43].
The OC prognostic signature we have developed based on IGV, is able to blindly predict
patient prognostic outcome in two independent data sets from studies by the Mayo Clinic and
TCGA (n = 198 and n = 358, respectively), with highly statistically significantly different clini-
cal outcomes between these groups (p = 0.004 in both data sets). The methodology we present
here is, after calibration on a training data-set, able to classify patients one by one without ref-
erence to any more new samples into better and worse prognostic groups. Thus, our method
gives a prediction of better or worse prognosis individually to patients. For this reason, it can
be considered to be a true prognostic measure.
It is becoming increasingly clear that understanding intra-tumour heterogeneity, is crucial
to understanding cancer biology [22, 23], including ovarian cancer [44], and recent work has
shown the effectiveness of intra-tumour heterogeneity as a prognostic marker [45]. Asking the
question, what is IGV, we examined whether intra-tumour methylation heterogeneity might be
a reflection of IGV, finding that while for genes with relatively low IGV this may be true, for
genes with high IGV, intra-tumour methylation heterogeneity does not appear to reflect IGV.
Therefore, we may hypothesise that in these genes, IGV represents a tumour-cell inherent phe-
nomenon. Investigating further the reasons for this phenomenon, by looking at binding of TFs
and the correlation of their expression with IGV of genes they bind to, revealed a distinctive
pattern of TF binding to different groups of genes, and identified a panel of TFs which are
highly associated with prognostic IGV. However, the TF binding maps we analysed here is not
exhaustive, and so this picture can be expected to become fuller, as more such TF binding data
become available. We have also found evidence of the importance of CpG islands to the func-
tional role of IGV in the genes of our prognostic signature and clusters.
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Cancer is a heterogenous disease, which can, even within the same tissue type, show very
different molecular characteristics between patients. Hence, it is becoming clear that for our
mechanistic understanding of cancer to progress, we must focus on large-scale data-sets (i.e,
‘big-data’), which are able to capture such heterogeneity with sufficient statistical power [45,
46]. Such analyses require computational statistical tools which are relatively new to medical
science, which in turn requires interdisciplinary collaboration. In this study, we have made use
of several such tools, to derive our prognostic signature gene-panel, and then to identify com-
mon molecular patterns within this gene-panel, which reflect heterogenous oncogenic pro-
cesses. The methodology we present here is computationally efficient, and would naturally
scale well to larger data-sets, and would be applicable to analysis of cancer data from a wide
range of tissues of origin.
We have conclusively demonstrated that our OC prognostic signature is an effective and
robust prognostic tool, and we also hypothesise that it is an easy to measure surrogate for dis-
ease processes mediated by specific transcription factors. IGV is a robust prognostic marker,
which is independent of known clinical prognostic factors.
Methods
Data and preprocessing
The main ovarian cancer (OC) data set, which was used to derive the OC prognostic signature,
consists of 221 samples each of which was taken from a different patient, of whom 158 died
from the disease before the end of the study. For each sample, a DNAmethylation profile col-
lected via the Illumina Infinium HumanMethylation450 platform was available, together with
information on the clinical variables survival status (alive or not), survival time (i.e., time to last
follow up or time to death), disease stage (I-IV), disease grade (1–3), and residual disease status
(present or not). 3 samples were removed due to missing clinical data, leaving the the n = 218
samples used to derive the OC prognostic signature. A further 9 samples were excluded from
the multivariate analysis of the IGV prognostic score, due to additional missing clinical data.
An independent data set from a study of OC carried out by the Mayo Clinic was used for
validation of the OC prognostic signature. Data from this study similarly included a DNA
methylation profile for each sample collected via the Illumina Infinium HumanMethylation450
platform; clinical data was also available for this data set for the same variables as the main OC
data set. There were n = 198 samples in this data set, of whom 115 died from the disease before
the end of the study. 49 samples were excluded from the multivariate analysis of the IGV prog-
nostic score, due to missing clinical data.
An additional independent data set from a study of uterine corpus endometrioid carcinoma
(UCEC) for further validation of the OC prognostic signature was downloaded with the The
Cancer Genome Atlas (TCGA) project [21]. Data from this study similarly included a DNA
methylation profile for each sample collected via the Illumina Infinium HumanMethylation450
platform, which was downloaded at level 3; clinical data was also downloaded if possible for
each sample for the same variables as the OC data set. There were 358 samples in this data set,
of whom 32 died from the disease before the end of the study. 50 samples were excluded from
the multivariate analysis of the IGV prognostic score, due to missing clinical data.
For the intra-tumour heterogeneity analysis, we considered two data sets, one from endo-
metrial cancer (EC) (samples from multiple metastatic sites for each of 10 patients), and one
from prostate cancer [23] (multiple samples from the same tumour for each of 5 patients). For
comparison with cross-patient methylation heterogeneity, we downloaded DNAm data for
breast cancer invasive carcinoma (BRCA) basal samples from TCGA (42 samples). Each of
these data-sets included a DNAmethylation profile for each sample collected via the Illumina
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Infinium HumanMethylation450 platform, again downloaded at level 3 for the TCGA BRCA
data-set. For the gene expression analysis in BRCA basal samples, we downloaded gene expres-
sion data for the same 42 samples from TCGA, at level 3.
Probes with non-unique mappings and which map to SNPs had already been removed from
the UCEC and BRCA TCGA DNAm data before they were downloaded, and these same
probes were also removed from the other DNAm data sets. Probes mapping to sex chromo-
somes were also removed (by prior agreement); in total 98384 probes were removed from the
DNAm data sets, of the 482421 probes originally present on the array. After removal of these
probes, 270985 probes with known gene annotations remained. Individually for each data set,
probes were then removed if they had less than 95% coverage across samples; probe values
were also replaced if they had corresponding detection p-value greater than 5%, by KNN (k
nearest neighbour) imputation (k = 5).
A summary of the data-sets analysed here appears in Table 1. A detailed summaries of the
patient cohorts of the main ovarian and uterine cancer DNAmethylation data-sets analysed
here appear in Table 2.
Per-gene methylation measures
Four per-gene measures were tested, as follows:
• TSS200 mean The mean methylation level of the probes annotated to the TSS200 region,
which is the region within 200bp upstream of the TSS (transcriptional start site); approxi-
mately the promoter region.
• TSS200 IGV The variance of the methylation level of the probes annotated to the TSS200
region.
• Gene body mean The mean methylation level of the probes annotated to the gene body.
• Gene body IGV The variance of the methylation level of the probes annotated to the gene
body.
To calculate these measures, annotation information specifying which probes map to each
gene and genomic region was used, as downloaded from Gene Expression Omnibus (GEO)
[47], and as part of the R / Bioconductor software package IlluminaHumanMethylation450k.
The mean methylation was calculated for genes with any number of probes annotated to the
relevant genomic region (12970 and 15839 genes for TSS200 and gene body respectively). The
Table 1. Data-sets analysed.
Data-set Patients Samples per patient Deaths Removed
Main OC DNAm 221 NA 158 12
Mayo OC DNAm 198 NA 115 49
TCGA UCEC DNAm 358 NA 32 50
Endometrial ITH DNAm 10 2–3 NA NA
Prostate ITH DNAm 5 16 NA NA
TCGA BRCA basal DNAm 42 NA NA NA
TCGA BRCA basal Expr 42 NA NA NA
Abbreviations: ITH, intra-tumour heterogeneity; DNAm, DNA methylation; OC, ovarian cancer; UCEC, uterine corpus endometrial carcinoma; BRCA,
breast cancer invasive carcinoma.
doi:10.1371/journal.pone.0143178.t001
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methylation variance was calculated for genes with at least 3 probes annotated to the relevant
genomic region (7557 and 10014 genes for TSS200 and gene body respectively).
Cross-validation to compare per-gene methylation measures and derive
OC prognostic signature
The samples (patients) of the main OC data-set were randomly split in to a ‘training set’ (2/3 of
the data, 145 samples) and a ‘test set’ (the remaining 1/3 of the data, 73 samples). The Elastic
Net [13, 14] was used to select a prognostic group of genes and fit a predictive model to these
genes based on the training set; this model was then assessed using the test set. This was
repeated 2001 times for each of the four per-gene methylation measures.
As the aim here is to predict clinical outcome, the Elastic Net was used in its penalised Cox
regression form, as implemented in the R package GLMNET [14]. Cox regression fits the model
by setting the model coefficients so as to maximise the partial likelihood, as defined by Eq (1),
LðθÞ ¼
Y
j2S
eθ
>xjP
j02Rj e
θ>xj0
; ð1Þ
where θ denotes the vector of model coefﬁcients, xj and xj0 are the vectors of predictor variable
values for samples j and j0 respectively (here, per-gene methylation measures), S is the set of
patients who died during the study, and Rj is the set of samples ‘at risk’ during the time interval
when patient j died, deﬁned as Rj = {j0|Yj0  Yj}, where Yj and Yj0 are the times of death of
patients j and j0 respectively. The Elastic Net penalises the log-likelihood corresponding to Eq
(1), constraining it according to the magnitude of the model ﬁt coefﬁcients, by subtracting this
constraint from the likelihood; in doing so, it ‘chooses’ the best combination of predictor vari-
ables (per-gene methylation measures), by adjusting the corresponding model coefﬁcients, and
setting these coefﬁcients to zero where the variables provide no useful information or redundant
information. The constraint is a combination of some multiples of the L1 and L2 norms of the
model ﬁt coefﬁcients; the severity and balance of the constraint is controlled by the parameters
λ (a ‘magnitude’ parameter) and α (a ‘blending’ parameter). Hence, the Elastic Net Cox model is
ﬁtted by ﬁnding model coefﬁcients θ^ which maximise the penalised log likelihood ϕ(θ, λ, α) in
Eq (2),
ðθ; l; aÞ ¼ 2
N
lðθÞ  l a k θ kL1 þ
ð1 aÞ
2
k θ k2L2
 
; ð2Þ
where N is the number of samples, k  kL1 and k  kL2 are the L1 and L2 norms, and l(θ) = log(L
(θ)). The R package GLMNET used for these model ﬁts sets the λ parameter internally using
ten-fold cross validation, and requires the user to set the α parameter (0 α 1), which was in
this case set by choosing the value which minimises the model error after trialling values from 0
to 1 in evenly-spaced intervals of 0.1. Model ﬁtting in this way leads to a set of model coefﬁcients
θ^ for a particular set of predictors (i.e., genome-wide per-gene methylation measures), with one
Table 2. Patient cohort details of the main DNAmethylation data-sets analysed.
Data-set Total patients Stage 3–4 Grade 3 Age 60 or over Residual disease
Main OC 221 183 (83%) 144 (65%) 94 (43%) 92 (42%)
Mayo OC 198 158 (80%) 164 (83%) 114 (58%) 70 (35%)
TCGA UCEC 358 103 (28%) 226 (63%) 241 (67%) 47 (18%)
doi:10.1371/journal.pone.0143178.t002
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coefﬁcient per predictor, deﬁning those predictors which are present in the model (i.e., predic-
tors with corresponding non-zero coefﬁcients), and their relative weightings.
The fitted model coefficients θ^ calculated according to Eqs (1) and (2) and the training set
data were used to calculate a score θ^>xj for each patient j, based on the corresponding per-
gene methylation measures xj. These scores were then used to divide the training set into ter-
tiles, deﬁning high and low risk groups. The cutoffs deﬁning the top and bottom tertiles in the
training set were then used to divide the test set into three portions, and those most and least at
risk (i.e., those test set patients with scores above the top cutoff, and below the bottom cutoff)
were compared by Mantzel-Haenszel test, stratiﬁed for age, stage and residual disease (disease
grade was not associated with survival for this data set), to assess the ability of this model ﬁt to
blindly predict patient survival, adjusted for signiﬁcant clinical covariates. Upper and lower ter-
tiles were compared here as previously by other authors [9] for the OC prognostic signature
generation, and the reasoning for doing so in this discovery stage, rather than comparing two
groups separated by the median score, was in order to prioritise larger effect sizes. If the sam-
ples were split into two groups divided by the median score, relatively small differences in the
per-gene methylation measures used to generate this score might result in patients being cate-
gorised as high or low risk, with corresponding signiﬁcant test results from this small variation
between patients. Comparison of upper and lower tertiles would be expected to be more robust
/ stable with respect to such small differences in per-gene methylation measures.
Due to the heterogeneity in the main OC data set which was used to generate the OC prog-
nostic signature, each randomly-selected training set which the Elastic Net model was fitted to
lead to a different set of genes being chosen. In order to infer a consistent OC prognostic signa-
ture from this data set, i.e., a consensus, the same process of randomly partitioning the data
and fitting the model was repeated a total of 105 times for the gene-body IGV measure. Of
these, 8281 model fits were able to significantly predict survival in the respective test set (FDR
q< 0.1). To generate the OC prognostic signature, genes were first ranked by how many of
these 8281 significant model fits they appeared in. In the case of ties, genes were additionally
ranked by, for each model fit, calculating the proportion of the sum of the absolute coefficient
values for that model, which each gene selected as part of that model accounted for, and then
comparing, for each tied gene, the mean of these proportions for that gene, across all the mod-
els it was selected as part of. Genes were assigned significance according to how many models
they were selected as being part of, y, out of the total k = 8281 models selected as significantly
associated with survival, under the null hypothesis that they were present in these observed y
significant model fits by chance. If there were the same number of genes selected as part of
each of these 8281 model fits, then this significance under the null hypothesis might be mod-
elled by a binomial distribution, with the probability pb of any gene being selected by chance as
part of one model fit approximated by pb = f/m, where f is the number of genes selected as part
of each and every model fit, andm is the total number of genes for which gene-body methyla-
tion variance information is available. The probability of seeing a gene purely by chance in at
least ymodel fits, out of a possible total of k, with constant probability pb of appearing in each
of these kmodels, would then be given by Eq (3),
PðY  yÞ ¼
Xk
r¼y
k
r
 !
prb 1 pbð Þ krð Þ
" #
: ð3Þ
However, the number of genes selected, f, as part of each model, varies considerably (from 7 to
1697), and consequently pb cannot be assumed to be constant. Alternatively, pb could be mod-
elled as being variable and bounded on [0, 1], with a corresponding probability distribution πb
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(pb). The distribution πb (pb) can be estimated as the observed distribution of f among the
k = 8281 signiﬁcant model ﬁts, again using pb = f/m. This leads to a modelled probability, Eq
(4), of seeing any gene at least y times out of kmodel ﬁts purely by chance, with pb variable and
with its distribution πb(pb) empirically estimated as p^b pbð Þ,
PðY  yÞ ¼
Xk
r¼y
Z1
0
p^b pbð Þ
k
r
 !
prb 1 pbð Þ krð Þ
" #
dpb
8<
:
9=
;; ð4Þ
with the square brackets included in Eq (4) to highlight the comparison with Eq (3). In practice,
the integral in Eq (4) is replaced with a sum over the observed values of pb, as calculated from
the observed values of f, which range between 7 and 1697. A kernel-smoothed plot of p^b pbð Þ, the
empirical probability density distribution of f and corresponding pb, appears in Fig 7.
Calculation of the DNAm IGV ovarian cancer prognostic score
Clustering was performed to identify groups of genes in the OC prognostic signature with simi-
lar patterns of IGV across patients. The clustering was carried out separately for genes individ-
ually associated with worse patient survival outcome for increased IGV (‘hyper’ genes) and for
decreased IGV (‘hypo’ genes). Consensus clustering [19] was used for the clustering, with a
Fig 7. Probability density distribution of the probabilities of a gene being included in a fitted model.
The plot shows a kernel-smoothed empirical estimate of the probability density distribution of the number of
genes included in each model, f, over the 8281 significant gene body methylation variance model fits, with
corresponding probability of a gene being included in a model pb = f/m, wherem is the number of genes with
gene body methylation variance information available.
doi:10.1371/journal.pone.0143178.g007
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hierarchical clustering inner loop, using 1 − ρ as the distance measure, where ρ is the Spearman
rank correlation coefficient. The following additional settings were used: probability of select-
ing a sample = 0.8, probability of selecting a feature = 1, number of resamplings = 105, maxi-
mum number of clusters = 20.
The discovered clusters were then filtered (to remove noise, and uncertainty associated with
trends inferred from small groups of genes in these genome-wide data), retaining only those
clusters which contained at least 10 genes, and only those clusters with mean IGV significantly
associated with patient survival outcome. After filtering, four clusters remained, for two of
which an increase in the cluster mean IGV was associated with worse patient survival outcome
(called ‘hyper 1’ and ‘hyper 2’), and for two of which a decrease in the cluster mean IGV was
associated with worse survival outcome (called ‘hypo 1’ and ‘hypo 2’). The IGV cluster scores
were then calculated, as the means of the IGV of the genes each of these four clusters.
In order to calculate the IGV prognostic score from these components, a Cox model (adjusted
for clinical covariates) was fitted to these four IGV cluster scores. The coefficients for this model
(standardised by the variance of the predictors) are fairly similar for each of the clusters (hyper 1:
0.22; hyper 2: 0.25; hypo 1: 0.23; hypo 2: 0.30), indicating that each cluster is important to the
model, and to the prognostic predictions. The median of the IGV prognostic score calculated
from this Cox model was used to divide the 218 patients in the main DNAmOC data-set used to
derive the OC prognostic signature, into better and worse prognostic groups.
Validation of the ovarian cancer prognostic signature
The DNAm prognostic signature derived from the OC data set was validated in two indepen-
dent DNAm data sets. The first of these data sets was taken from another study of OC
(n = 198), and was supplied by the Mayo Clinic. The second of these data sets was taken from a
study of uterine corpus endometrioid carcinoma (UCEC) (n = 358), and was downloaded from
The Cancer Genome Atlas (TCGA) project [21].
The IGV prognostic score was similarly calculated by fitting a Cox model to the four IGV
cluster scores in the main OC DNAm data set, adjusted for clinical covariates, then applying
this model to the equivalent IGV cluster scores in the Mayo Clinic OC and the TCGA UCEC
validation sets. In order to make prognostic predictions in these independent data sets using
only the DNAm data, the model was used to calculate the IGV prognostic score for the samples
in the independent data sets from the fitted model coefficients corresponding to IGV cluster
scores only, and not the clinical covariates. This IGV prognostic score was used to define better
and worse prognostic groups in the independent data sets, separated by the median IGV prog-
nostic score in the main OC data set. These prognostic groups were then compared, assessing
statistical significance with univariate and multivariate Cox regression (i.e., respectively with-
out and with adjustment for the clinical covariates).
Comparison of IGV with Intra-Tumour Heterogeneity
Intra-tumour methylation heterogeneity was assessed in terms of cross-sample variability of
methylation, where the samples are taken from the same patient. The resulting patterns and
relationships are compared with cross-sample variability of methylation in the main OC data
set, where the samples are now from different patients. Cross-sample variability of methylation
is estimated by first calculating the variance of the methylation measurements across all sam-
ples for a particular probe, and then taking the mean of these probe variances for all the probes
in a gene (gene body probes only). This mean cross-sample methylation variance was com-
pared to the mean IGV of the same gene, which is calculated by taking the mean of the IGV for
that gene across the same samples as were used to calculate the cross-sample methylation
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variance. Cross-sample methylation variance was then analysed as a function of IGV by esti-
mating E yjxð Þ, where y represents cross-sample methylation variance and x represents IGV, by
ﬁtting spline curves. This resulted in one best-ﬁt curve per patient for the EC and prostate can-
cer intra-tumour heterogeneity datasets, and one best-ﬁt curve for all the patients for each of
the main OC and TCGA BRCA basal datasets.
Testing Transcription-factor binding correlation with IGV
We examined transcription factor binding to the OC prognostic signature genes, using the
ENCODE (Encyclopedia of DNA Elements) chromatin immunoprecipitation (ChIP) data
[24], with the ANNOVAR software [48]. Transcription factor binding site information was
available, for the gene body regions defined, for 55 transcription factors. Each of these TFs was
tested for significant over or under enrichment binding to the genes of each of the four prog-
nostic signature clusters, with Fisher’s exact test. We also tested the correlation of the expres-
sion level of each of these 55 TFs, with the IGV of genes the TF binds to, and the genes the TF
does not bind to. We used a Kolmogorov-Smirnov test to assess whether, for each TF, there is
significantly more positive, or more negative, correlation with IGV of the genes it binds to,
compared to genes it does not. For this expression correlation analysis, we used the 42 TCGA
BRCA basal samples with both expression and DNAm data available, because it was compre-
hensively demonstrated by the TCGA consortium that high-grade serous ovarian and uterine
and BRCA basal cancers are extremely molecularly similar [25], and we also established a high
degree of similarity of behaviour between our prognostic signature genes in OC, and these
TCGA BRCA basal samples.
Ethics Statement
The use of tumour tissue has been approved by the local ethical committees of the contributing
institutions: Studying the samples contributed from Rotterdam has been approved by the local
Rotterdam Medical Ethics Committee (MEC-2008-183), performed in accordance with the
Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (http://
www.fmwv.nl). The Regional Committee for Medical Research Ethics in Norway approved the
study (for ovarian cancer patients diagnosed in Oslo before 2007, exemption from obtaining
informed consent was received as the majority of ovarian cancer patients were dead at the time
the application was evaluated; patients diagnosed after 2007 signed general consent allowing
for use of the tumours for research purposes). Written informed consent for the use of tumour
tissue and prospective clinical data collection was obtained from all patients and approved by
the Leuven ethics committee. The use of cancer samples from Bergen was approved by the
Regional Research Ethics Committee in Medicine and patients have given their written
informed consent to use their sample for research. Patients whose samples were used from the
Mayo Clinic gave informed consent and the Mayo Clinic Institutional Review Board approved
the study. No identifying patient information was available to us. The data have not been pub-
lished before.
Supporting Information
S1 Fig. Mean IGV across patients, for the genes of each cluster.
(TIF)
S2 Fig. Mean gene-body methylation level, across patients, for the genes of each cluster.
(PDF)
DNAMethylation Variability Is a Prognostic Marker
PLOS ONE | DOI:10.1371/journal.pone.0143178 December 2, 2015 19 / 22
S1 File. Supplementary Tables.
(PDF)
Acknowledgments
We are very grateful to all specimen donors and research groups involved in providing the data
used in this study via TCGA and GEO. This work was funded (MW and AJ) by the European
Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement number
305428 (Project EpiFemCare), by the National Institute for Health Research University College
London Hospitals Biomedical Research Centre, and by the Eve Appeal and the European Net-
work Translational Research in Gynaecological Oncology (ENTRIGO) of the European Society
of Gynaecological Oncology (ESGO). TEB received funding from the UK Engineering and
Physical Sciences Research Council (ESPRC) and the UKMedical Research Council (MRC) via
UCL CoMPLEX. ELG received funding from the Fred C. and Katherine B. Andersen Founda-
tion, NIH grants R01-CA122443, P50-CA136393 (the Mayo Clinic Ovarian Cancer SPORE)
and P30-CA15083. The funders had no role in study design, data collection and analysis, deci-
sion to publish, or preparation of the manuscript.
Author Contributions
Conceived and designed the experiments: TEB MW. Performed the experiments: AJ JMC.
Analyzed the data: TEB MW. Contributed reagents/materials/analysis tools: ELG BLF EW
HBS BD CGT SL IV EMJJB. Wrote the paper: TEB MW.
References
1. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nature
Reviews Genetics. 2006; 7(1):21–33. doi: 10.1038/nrg1748 PMID: 16369569
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Reviews Genetics.
2002; 3(6):415–428. PMID: 12042769
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Jour-
nal for Clinicians. 2011; 61(2):69–90.
4. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA: A Cancer Journal for Cli-
nicians. 2001; 51(1):15–36.
5. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell
signature in cancer. Nature Genetics. 2006; 39(2):157–158. doi: 10.1038/ng1941 PMID: 17200673
6. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nature Reviews Genet-
ics. 2007; 8(4):253–262. doi: 10.1038/nrg2045 PMID: 17363974
7. Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and implications. Nature
Reviews Genetics. 2012; 13(2):97–109. PMID: 22215131
8. Bartlett TE, Olhede SC, Zaikin A. A DNAMethylation Network Interaction Measure, and Detection of
Network Oncomarkers. PloS One. 2014; 9(1):e84573. doi: 10.1371/journal.pone.0084573 PMID:
24400102
9. Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, et al. The Dynamics and Prognostic Potential of
DNAMethylation Changes at Stem Cell Gene Loci in Women’s Cancer. PLoS Genetics. 2012; 8(2):
e1002517. doi: 10.1371/journal.pgen.1002517 PMID: 22346766
10. Jaffe AE, Feinberg AP, Irizarry RA, Leek JT. Significance analysis and statistical dissection of variably
methylated regions. Biostatistics. 2012; 13(1):166–178. doi: 10.1093/biostatistics/kxr013 PMID:
21685414
11. Hansen KD, TimpW, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, et al. Increased methyla-
tion variation in epigenetic domains across cancer types. Nature Genetics. 2011; 43(8):768–775. doi:
10.1038/ng.865 PMID: 21706001
12. Bartlett TE, Zaikin A, Olhede SC, West J, Teschendorff AE, Widschwendter M. Corruption of the Intra-
Gene DNAMethylation Architecture Is a Hallmark of Cancer. PloS One. 2013; 8(7):e68285. doi: 10.
1371/journal.pone.0068285 PMID: 23874574
DNAMethylation Variability Is a Prognostic Marker
PLOS ONE | DOI:10.1371/journal.pone.0143178 December 2, 2015 20 / 22
13. Zou H, Hastie T. Regularization and variable selection via the elastic net. Journal of the Royal Statistical
Society: Series B (Statistical Methodology). 2005; 67(2):301–320. doi: 10.1111/j.1467-9868.2005.
00503.x
14. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via
coordinate descent. Journal of Statistical Software. 2011; 39(5):1–13. doi: 10.18637/jss.v039.i05
15. Jojic V, Shay T, Sylvia K, Zuk O, Sun X, Kang J, et al. Identification of transcriptional regulators in the
mouse immune system. Nature Immunology. 2013; 14(6):633–643. doi: 10.1038/ni.2587 PMID:
23624555
16. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to
Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995; 57(1):289–
300.
17. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification
of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286
(5439):531–537. doi: 10.1126/science.286.5439.531 PMID: 10521349
18. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, van Doorn-Khosrovani SBvW, Boer JM, et al. Prognos-
tically useful gene-expression profiles in acute myeloid leukemia. New England Journal of Medicine.
2004; 350(16):1617–1628. doi: 10.1056/NEJMoa040465 PMID: 15084694
19. Monti S, Tamayo P, Mesirov J, Golub T. Consensus clustering: a resampling-based method for class
discovery and visualization of gene expression microarray data. Machine Learning. 2003; 52(1–2):91–
118. doi: 10.1023/A:1023949509487
20. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression.
American Journal of Epidemiology. 2007; 165(6):710–718. doi: 10.1093/aje/kwk052 PMID: 17182981
21. Collins F, Barker A. Mapping the cancer genome. Scientific American Magazine. 2007; 296(3):50–57.
doi: 10.1038/scientificamerican0307-50
22. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diver-
sity in genomic instability processes defines lung cancer evolution. Science. 2014; 346(6206):251–
256. doi: 10.1126/science.1253462 PMID: 25301630
23. Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, et al. Intratumor DNAmethylation
heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell reports. 2014; 8(3):798–806.
doi: 10.1016/j.celrep.2014.06.053 PMID: 25066126
24. Consortium EP, et al. The ENCODE (ENCyclopedia of DNA elements) project. Science. 2004; 306
(5696):636–640. doi: 10.1126/science.1105136
25. Network CGA, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490
(7418):61–70. doi: 10.1038/nature11412
26. Nitzsche A, Paszkowski-Rogacz M, Matarese F, Janssen-Megens EM, Hubner NC, Schulz H, et al.
RAD21 cooperates with pluripotency transcription factors in the maintenance of embryonic stem cell
identity. PloS One. 2011; 6(5):e19470. doi: 10.1371/journal.pone.0019470 PMID: 21589869
27. Attanasio C, Nord AS, Zhu Y, Blow MJ, Biddie SC, Mendenhall EM, et al. Tissue-specific SMARCA4
binding at active and repressed regulatory elements during embryogenesis. Genome research. 2014;
24(6):920–929. doi: 10.1101/gr.168930.113 PMID: 24752179
28. Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, et al. Germline and
somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
Nature Genetics. 2014; 46(5):438–443. doi: 10.1038/ng.2931 PMID: 24658002
29. Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, et al. Small cell carcinoma of
the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in
SMARCA4. Nature genetics. 2014; 46(5):427–429. doi: 10.1038/ng.2928 PMID: 24658001
30. Jelinic P, Mueller JJ, Olvera N, Dao F, Scott SN, Shah R, et al. Recurrent SMARCA4 mutations in small
cell carcinoma of the ovary. Nature Genetics. 2014; 46(5):424–426. doi: 10.1038/ng.2922 PMID:
24658004
31. Gartel A. A newmode of transcriptional repression by c-Myc: methylation. Oncogene. 2006; 25
(14):1989–1990. doi: 10.1038/sj.onc.1209101 PMID: 16170342
32. Yokomori N, Tawata M, Saito T, Shimura H, Onaya T. Regulation of the rat thyrotropin receptor gene
by the methylation-sensitive transcription factor GA-binding protein. Molecular Endocrinology. 1998; 12
(8):1241–1249. doi: 10.1210/mend.12.8.0142 PMID: 9717849
33. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J, et al. TET1 and hydro-
xymethylcytosine in transcription and DNAmethylation fidelity. Nature. 2011; 473(7347):343–348. doi:
10.1038/nature10066 PMID: 21490601
DNAMethylation Variability Is a Prognostic Marker
PLOS ONE | DOI:10.1371/journal.pone.0143178 December 2, 2015 21 / 22
34. Kirillov A, Kistler B, Mostoslavsky R, Cedar H, Wirth T, Bergman Y. A role for nuclear NF–κB in B–cell–
specific demethylation of the Igκ locus. Nature Genetics. 1996; 13(4):435–441. doi: 10.1038/ng0895-
435 PMID: 8696338
35. Zechner U, Seifert D, Schneider E, El Hajj N, Navarro B, Kondova I, et al. Different DNAmethylation of
FOXP2 target genes in adult cortices of humans and chimpanzees. In: Proceedings of the Annual
Meeting of the American Society of Human Genetics. American Society of Human Genetics; 2012.
p. 3266W.
36. Coulson JM. Transcriptional regulation: cancer, neurons and the REST. Current biology. 2005; 15(17):
R665–R668. doi: 10.1016/j.cub.2005.08.032 PMID: 16139198
37. Gustems M,Woellmer A, Rothbauer U, Eck SH, Wieland T, Lutter D, et al. c-Jun/c-Fos heterodimers
regulate cellular genes via a newly identified class of methylated DNA sequence motifs. Nucleic Acids
Research. 2014; 42(5):3059–3072. doi: 10.1093/nar/gkt1323 PMID: 24371273
38. Ng CW, Yildirim F, Yap YS, Dalin S, Matthews BJ, Velez PJ, et al. Extensive changes in DNAmethyla-
tion are associated with expression of mutant huntingtin. Proceedings of the National Academy of Sci-
ences. 2013; 110(6):2354–2359. doi: 10.1073/pnas.1221292110
39. Malone CS, Miner MD, Doerr JR, Jackson JP, Jacobsen SE, Wall R, et al. CmC (A/T) GG DNAmethyl-
ation in mature B cell lymphoma gene silencing. Proceedings of the National Academy of Sciences.
2001; 98(18):10404–10409. doi: 10.1073/pnas.181206898
40. ZhuWG, Srinivasan K, Dai Z, DuanW, Druhan LJ, Ding H, et al. Methylation of adjacent CpG sites
affects Sp1/Sp3 binding and activity in the p21Cip1 promoter. Molecular and Cellular Biology. 2003; 23
(12):4056–4065. doi: 10.1128/MCB.23.12.4056-4065.2003 PMID: 12773551
41. Jones PA. Functions of DNAmethylation: islands, start sites, gene bodies and beyond. Nature Reviews
Genetics. 2012; 13(7):484–492. doi: 10.1038/nrg3230 PMID: 22641018
42. Consortium EP, et al. An integrated encyclopedia of DNA elements in the human genome. Nature.
2012; 489(7414):57–74. doi: 10.1038/nature11247
43. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene
expression and is a therapeutic target in cancer. Cancer cell. 2014; 26(4):577–590. doi: 10.1016/j.ccr.
2014.07.028 PMID: 25263941
44. Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Spatial and Temporal Hetero-
geneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis. PLoS medicine. 2015; 12(2):
e1001789. doi: 10.1371/journal.pmed.1001789 PMID: 25710373
45. Mroz EA, Tward AM, Hammon RJ, Ren Y, Rocco JW. Intra-tumor Genetic Heterogeneity and Mortality
in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas. PLoS medicine. 2015; 12
(2):e1001786. doi: 10.1371/journal.pmed.1001786 PMID: 25668320
46. Beck AH. Open Access to Large Scale Datasets Is Needed to Translate Knowledge of Cancer Hetero-
geneity into Better Patient Outcomes. PLoSmedicine. 2015; 12(2):e1001794. doi: 10.1371/journal.
pmed.1001794 PMID: 25710538
47. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization
array data repository. Nucleic Acids Research. 2002; 30(1):207–210. doi: 10.1093/nar/30.1.207 PMID:
11752295
48. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-through-
put sequencing data. Nucleic Acids Research. 2010; 38(16):e164–e164. doi: 10.1093/nar/gkq603
PMID: 20601685
DNAMethylation Variability Is a Prognostic Marker
PLOS ONE | DOI:10.1371/journal.pone.0143178 December 2, 2015 22 / 22
